Efficacy and Safety of THDB0206 Compared to Insulin Lispro Injection in Participants With Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1040 participants.

Also called NCT05834868

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,040 participants (enrolled count) (from the registry)
Sponsor
Tonghua Dongbao Pharmaceutical Co.,Ltd (from the registry)
Registry
  • NCT NCT05834868
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05834868. Randomized; no masking; primary purpose treatment. Start 2022-05-06 (actual); primary completion 2024-12-10 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of THDB0206 Compared to Insulin Lispro Injection in Participants With Type 2 Diabetes
Intervention (Drug)
THDB0206 Injection
Intervention (Drug)
Insulin Lispro Injection
Lead sponsor
Tonghua Dongbao Pharmaceutical Co.,Ltd (class: industry)

Record details

Record id
cardio:ct-nct05834868
Content hash
70bfb55d57e3daf88b7665a676906b1e6bd4c887f9b90df240eb4292ef8a3a59